{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:29:14Z","timestamp":1784950154964,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000190","name":"University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000190","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Marshall Eliuk Fund and University Hospital Foundation","award":["SFR1404"],"award-info":[{"award-number":["SFR1404"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jmoldx.2019.10.002","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T12:32:11Z","timestamp":1574080331000},"page":"208-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Clinical Validation of a Myeloid Next-Generation Sequencing Panel for Single-Nucleotide Variants, Insertions\/Deletions, and Fusion Genes"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2906-6620","authenticated-orcid":false,"given":"Iyare","family":"Izevbaye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9409-7370","authenticated-orcid":false,"given":"Li Y.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Mather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soufiane","family":"El-Hallani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7562-5254","authenticated-orcid":false,"suffix":"Jr.","given":"Remegio","family":"Maglantay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2019.10.002_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib2","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib3","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib4","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib6","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib7","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib8","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib9","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/ajcp\/aqw016","article-title":"Targeted next-generation sequencing in myelodysplastic syndrome and chronic myelomonocytic leukemia aids diagnosis in challenging cases and identifies frequent spliceosome mutations in transformed acute myeloid leukemia","volume":"145","author":"Reinig","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13000-016-0456-8","article-title":"Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms","volume":"11","author":"Au","year":"2016","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib12","doi-asserted-by":"crossref","first-page":"30084","DOI":"10.18632\/oncotarget.8310","article-title":"Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms","volume":"7","author":"Bartels","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jmoldx.2016.02.003","article-title":"Validation and implementation of a custom next-generation sequencing clinical assay for hematologic malignancies","volume":"18","author":"Kluk","year":"2016","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib14","doi-asserted-by":"crossref","first-page":"759","DOI":"10.5858\/arpa.2016-0547-RA","article-title":"Integration of technical, bioinformatic, and variant assessment approaches in the validation of a targeted next-generation sequencing panel for myeloid malignancies","volume":"141","author":"Thomas","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib15","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jmoldx.2018.07.002","article-title":"Clinical significance of DNA variants in chronic myeloid neoplasms: a report of the Association for Molecular Pathology","volume":"20","author":"McClure","year":"2018","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib17","doi-asserted-by":"crossref","first-page":"926","DOI":"10.6004\/jnccn.2017.0116","article-title":"Acute myeloid leukemia, version 3.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"O'Donnell","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib18","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib19","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2011-11-393264","article-title":"Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy","volume":"119","author":"Chendamarai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib20","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/bloodadvances.2018016378","article-title":"Evaluating measurable residual disease in acute myeloid leukemia","volume":"2","author":"Ravandi","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib21","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib22","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5045\/br.2014.49.4.216","article-title":"Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease","volume":"49","author":"Visconte","year":"2014","journal-title":"Blood Res"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib23","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1182\/blood-2012-11-469619","article-title":"BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders","volume":"122","author":"Damm","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2019.10.002_bib24","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152515781930409X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152515781930409X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:13:48Z","timestamp":1761502428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152515781930409X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S152515781930409X"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2019.10.002","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Validation of a Myeloid Next-Generation Sequencing Panel for Single-Nucleotide Variants, Insertions\/Deletions, and Fusion Genes","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2019.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}